TABLE 5.
Microbiological, pharmacokinetic, and pharmacodynamic information for patients with proven fungal infection
| IDa | Dose (mg/kg/day) | Pathogen (n = 11 cases)
|
Cmax,ss/ MIC | Efficacyc | |
|---|---|---|---|---|---|
| Fungi | MICb | ||||
| 3 | 5.4 | C. albicans | 0.50 | 88.4 | C |
| A. fumigatus | 1.00 | 44.2 | P | ||
| A. niger | 1.00 | 44.2 | P | ||
| 8 | 2.9 | A. fumigatus | 1.00 | 22.5 | P |
| 10b | 3.1 | A. fumigatus | 1.00 | 36.5 | P |
| 20b | 3.5 | C. krusei | 1.00 | 32.1 | P |
| 22 | 3.0 | Rhodotorula rubra | 0.25 | 68.8 | C |
| 32 | 4.8 | Scedosporium prolificans | 4.00 | 4.3 | F |
| 36a | 4.9 | C. albicans | 0.25 | 45.6 | C |
| 38 | 5.3 | C. albicans | 0.50 | 61.6 | P |
| 40 | 4.1 | C. albicans | 0.25 | 68.8 | C |
a
ID, patient identification number; a, the first course of L-AmB therapy; b, the second course of L-AmB therapy.
b
MIC of D-AmB (μg·ml−1).
c
C, complete response; P, partial response; F, failure to respond.